Aurora news releases
ABIOMED Announces First Sale of New AB5000 Console - St. Luke’s Medical Center in Milwaukee is First CustomerFriday, May 09, 2003ABIOMED, Inc. has announced that St. Luke’s Medical Center in Milwaukee, Wisconsin has acquired two AB5000™ Circulatory Support System consoles. St. Luke’s is the first hospital in the nation to adopt the new technology.
ABIOMED announced FDA approval to market the AB5000 console on May 1, 2003, and it was displayed for the first time at the American Association for Thoracic Surgery (AATS) meeting in Boston, Massachusetts from May 4-7. The AB5000 will drive and control one or two BVS® 5000 blood pumps, either in the hospital or for transport of patients between hospitals. Incorporating a state-of-the-art electronic interface, the AB5000 is designed to improve the convenience and ease-of-use of ABIOMED’s current BVS blood pump and to serve as a common platform for future heart assist blood pumps currently under development at ABIOMED.
According to Dr. Alfred Tector, Chief of Cardiac Surgery at St. Luke’s Medical Center, “The ABIOMED BVS 5000 pump has been very supportive to many acutely ill patients with poor heart function. The new console will make it easier to use the pump and it will be more beneficial to the patients.” Dr. Tector has been a long-standing ABIOMED customer. He added that he is “… looking forward to working with ABIOMED and to gaining clinical experience with the AB5000 Support System and future technologies.”
“We are gratified at the positive response we are receiving to the AB5000 console as well as to our further product development plans in the circulatory assist arena,” said Gene Rabe, ABIOMED’s Senior Vice President for Sales and Service. “St. Luke’s Medical Center first acquired our BVS technology in 1993, and has a decade of experience using the BVS 5000 for all short term circulatory assist indications. Their early decision to adopt the AB5000 tells us that we have a new product that will be responsive to the needs of our best customers.”
Based in Danvers, Massachusetts, ABIOMED, Inc. (pronounced “AB’-EE-O-MED”) is a leading developer, manufacturer and marketer of medical products designed to assist or replace the pumping function of the failing heart. ABIOMED, which currently sells the BVS 5000 Biventricular Support System and the AB5000 Circulatory Support System Console, is the market leader in devices for the temporary support of patients with failing but potentially recoverable hearts.
The Company’s AbioCor® Implantable Replacement Heart is the subject of an initial clinical trial being conducted under an Investigational Device Exemption from the United States Food and Drug Administration. The AbioCor has not been approved for commercial distribution, and is not available for use or sale outside of the initial clinical trial.